Prevention of 11-deoxycorticosterone-salt-induced glomerular hypertrophy and glomerulosclerosis by dietary phosphate binder.
The effects of dietary phosphate binder on deoxycorticosterone (DOC)-salt-hypertensive rats were examined. DOC-treated and non-DOC-treated rats were fed the diet either with or without phosphate binder, dihydroxyaluminum aminoacetate. All rats drank 1% NaCl. DOC-salt-treated rats without binder demonstrated marked glomerular hypertrophy, many globally sclerosed glomeruli, severe proteinuria, focal cardiac fibrosis, and splenomegaly. A significant reduction of glomerular hypertrophy, glomerulosclerosis, severity of proteinuria, splenomegaly, and the myocardial lesion took place when the DOC-salt-treated rats were given phosphate binder. The globally sclerosed glomeruli exhibited remarkable hypertrophy while structurally preserved glomeruli showed little evidence of enlargement. The plasma phosphate level was low in rats with dietary phosphate binder. In conclusion, the dietary phosphate binder ameliorated glomerular hypertrophy, glomerulosclerosis, proteinuria, myocardial fibrosis, and splenomegaly occurring in DOC-salt-treated rats. The data indicated that there was an association between glomerular hypertrophy and glomerulosclerosis in this model. The exact mechanisms of action of the phosphate binder, however, remain far from clear.
Shimamura
T
T
Department of Pathology, UMDNJ-RWJ Medical School, Piscataway 08854.
D000536:Aluminum Hydroxide / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D000863:Antacids / Q000008:administration & dosage / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D002118:Calcium / Q000097:blood; D003401:Creatine / Q000097:blood; D003900:Desoxycorticosterone; D004195:Disease Models, Animal; D005919:Glomerular Filtration Rate / Q000187:drug effects; D005921:Glomerulonephritis / Q000517:prevention & control*; D005923:Glomerulosclerosis, Focal Segmental / Q000139:chemically induced / Q000178:diet therapy / Q000517:prevention & control*; D005998:Glycine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006400:Hematocrit; D006984:Hypertrophy / Q000139:chemically induced / Q000178:diet therapy / Q000517:prevention & control; D007678:Kidney Glomerulus / Q000187:drug effects / Q000473:pathology*; D008297:Male; D009206:Myocardium / Q000473:pathology; D010710:Phosphates / Q000378:metabolism*; D011507:Proteinuria / Q000378:metabolism; D051381:Rats; D011919:Rats, Inbred Strains; D013154:Spleen / Q000187:drug effects / Q000473:pathology
D000863:Antacids; D010710:Phosphates; D003900:Desoxycorticosterone; D000536:Aluminum Hydroxide; C007420:dihydroxyaluminum aminoacetate; D003401:Creatine; D002118:Calcium; D005998:Glycine